Quantum Biopharma Ltd. Class B Subordinate Voting Shares
QNTM
Quantum BioPharma Ltd is a biopharmaceutical company dedicated to building a portfolio of inventive assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders with drug candidates in different stages of development. Through its wholly owned subsidiary, it is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company maintains a portfolio of strategic investments through its wholly owned subsidiary, which represents loans secured by residential or commercial property.
Last trade$1.54
Day change+$0.095 (+6.60%)
Day range$1.44 – $1.67
Volume150,866
Market cap$12M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for QNTM.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for QNTM.
Recent news
Company coverage with links to the original publishers.
Quantum BioPharma Ltd. filed a supplement to its management information circular ahead of its November 10, 2026 shareholder meeting, correcting the treatment of fractional shares in a proposed consolidation of its class A multiple voting shares and class B subordinate voting shares. The company also clarified that MVS holders' voting power will be capped at 70% if their aggregate voting power would otherwise exceed this threshold due to share cancellations.
Quantum BioPharma has entered into a Study Start-Up Agreement with Thermo Fisher Scientific's PPD Clinical Research Business to implement its Phase 2 clinical trial of Lucid-MS, an investigational neuroprotective therapy targeting demyelination in progressive multiple sclerosis. The agreement marks a significant milestone following FDA clearance and represents the initiation of formal study start-up activities.
Quantum BioPharma Ltd. closed a debt settlement of CAD$123,487.43 by issuing 30,948 Class B subordinate voting shares to creditors at CAD$3.99 per share. The company is a biopharmaceutical firm developing treatments for neurodegenerative, metabolic, and alcohol misuse disorders, with its lead compound Lucid-MS in preclinical development.
Quantum BioPharma Ltd. announced that its board of directors approved a debt settlement of CAD$123,487.43 to creditors and insiders through the issuance of Class B subordinate voting shares at a deemed price based on the lower of CAD$4.26 or the CSE closing price on the trading day prior to settlement closing.
Quantum BioPharma announced that its Lucid-MS (Lucid-21-302) investigational drug for multiple sclerosis treatment has been placed on clinical hold by the FDA pending submission of additional information. The company believes the issues are addressable and plans to submit a response package. Previously disclosed timelines for FDA review, Phase 2 trial initiation, and data milestones have been withdrawn. Additionally, Dr. Lakshmi P. Kotra resigned as director but will remain as a senior clinical advisor.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.